Murat Kalayoglu left the role of Director at Cartesian Therapeutics, Inc., effective March 31, 2026. As of November 7, 2026, Cartesian Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 30, 2026 to May 26, 2026, naming 1 departure (Form 8-K, March 30, 2026).
Who owns Cartesian Therapeutics, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Cartesian Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Cartesian Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-30 to 2026-05-26. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Cartesian Therapeutics, Inc. files it.
Also on the record for Cartesian Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Stake report, Schedule 13G/A, by Barclays PLC | 0.02% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13G, by Barclays PLC | 5.99% of the class | 5%+ stakes | Source |
| July 22, 2026 | Stake report, Schedule 13G/A, by JPMORGAN CHASE & CO. | 4.8% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 3% of the class | 5%+ stakes | Source |
| April 2, 2026 | Stake report, Schedule 13D/A, by Murat Kalayoglu | 19.9% of the class | 5%+ stakes | Source |
| March 13, 2026 | Stake report, Schedule 13G, by Squarepoint Ops LLC | 8.3% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 5.3% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 8.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Cartesian Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Cartesian Therapeutics, Inc. and the records around it.
Cartesian Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Squarepoint Ops LLC also filed stake reports on 1 other company: LENZ Therapeutics, Inc. (Apr 2026)
- Barclays PLC also filed stake reports on 116 other companies: BIGLARI HOLDINGS INC-B (Nov 2026), CABLE ONE INC (Nov 2026), CALISA ACQUISITION CORP (Nov 2026)
- JPMORGAN CHASE & CO. also filed stake reports on 116 other companies: LEVI STRAUSS & CO (Nov 2026), Warner Music Group Corp. (Nov 2026), Andersen Group Inc. (Oct 2026)
Watch Cartesian Therapeutics, Inc.
Get an email when Cartesian Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cartesian Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cartesian Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cartesian Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-26 | Reported | not named in the filing | 8-K, 2026-05-26 | ||
| 2026-03-30 | Out | Director | 2026-03-31 | 8-K, 2026-03-30 |
Who leads Cartesian Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Murat Kalayoglu, departure reported, effective 2026-03-31 (filed 2026-03-30). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Cartesian Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Cartesian Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Cartesian Therapeutics, Inc.Every change, in the filing's words
Reported
On May 22, 2026, Milos Miljkovic, M.D., the Company's Chief Medical Officer, delivered a notice of resignation to the Company.
- In connection therewith, the Company expects to enter into a separation agreement and release (the "Separation Agreement") with Dr. Miljkovic on or about May 31, 2026 (the "Execution Date"), pursuant to which Dr. Miljkovic's employment with the Company will cease May 31, 2026.
- A copy of the Separation Agreement is expected to be filed with the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.
Departing: Murat Kalayoglu, Director, effective 2026-03-31
On March 26, 2026, Murat Kalayoglu, M.D., Ph.D., a member of the Board of Directors (the "Board") of Cartesian Therapeutics, Inc. (the "Company"), notified the Company of his intent to resign from the Board, effective as of March 31, 2026, to pursue other opportunities.
- Prior to his resignation, Dr. Kalayoglu served as Chairman of the Board's Science and Technology Committee and as a member of the Board's Nominating and Corporate Governance Committee.
- In connection with his resignation from the Board, Dr. Kalayoglu will cease service on such committees.
- Dr. Kalayoglu's resignation was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Dr. Kalayoglu served on the Board since 2023.
- The Company thanks Dr. Kalayoglu for his advice and leadership as a member of the Board and wishes Dr. Kalayoglu well as he pursues other opportunities.
Tools for this story
Each opens in a new tab, filled in for Cartesian Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.